Triplet Therapeutics
George joined Triplet Therapeutics, Inc. in April 2020 and serves as VP, DMPK & Toxicology. With his 20 years of experience in the pharmaceutical industry, he is an expert in optimization and characterization of ADMET properties throughout the course of drug discovery and development.
He most recently served as Senior Director and Head of Translational ADME & PK/PD at Schrödinger Inc. In this role, George provided strong leadership to establish ADMET and PK/PD function for fast-paced drug discovery operation of various formats, including internal programs and external partnership. Prior to this recent experience, George had served as Senior Director and Head of DMPK at Eisai, Inc. In this role, he led a team that successfully completed high-quality regulatory submission packages for over ten diverse clinical candidates for immunology, oncology, and neurology indications. In an earlier role at Eisai, George made translational ADME and bioanalytical contributions that helped ensure the successful development of HALAVEN® (eribulin mesylate) from preclinical to clinical stages. Prior to joining Eisai, George worked as a Principal Scientist at Boehringer Ingelheim. He holds a Ph.D. in pharmaceutical science from the University of Toronto.
This person is not in any offices
Triplet Therapeutics
Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) -- a group of more than 50 known genetic diseases including Huntington’s disease, myotonic dystrophy, spinocerebellar ataxias, fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) -- leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs. Triplet is backed by investments from Atlas Venture, MPM Capital and Pfizer Ventures, along with Invus, Partners Innovation Fund and Alexandria Venture Investments.